🇺🇸 FDA
Patent

US 9326992

Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA

granted A61KA61K31/713A61K47/6455

Quick answer

US patent 9326992 (Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
86
CPC classes
A61K, A61K31/713, A61K47/6455, A61P, A61P43/00